IL165304A0 - Method of treating diabetes - Google Patents

Method of treating diabetes

Info

Publication number
IL165304A0
IL165304A0 IL16530403A IL16530403A IL165304A0 IL 165304 A0 IL165304 A0 IL 165304A0 IL 16530403 A IL16530403 A IL 16530403A IL 16530403 A IL16530403 A IL 16530403A IL 165304 A0 IL165304 A0 IL 165304A0
Authority
IL
Israel
Prior art keywords
treating diabetes
diabetes
treating
Prior art date
Application number
IL16530403A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL165304A0 publication Critical patent/IL165304A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL16530403A 2002-05-21 2003-05-21 Method of treating diabetes IL165304A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38278102P 2002-05-21 2002-05-21
US45933203P 2003-03-31 2003-03-31
PCT/US2003/016277 WO2003099281A2 (en) 2002-05-21 2003-05-21 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes

Publications (1)

Publication Number Publication Date
IL165304A0 true IL165304A0 (en) 2006-01-15

Family

ID=29586970

Family Applications (4)

Application Number Title Priority Date Filing Date
IL16530403A IL165304A0 (en) 2002-05-21 2003-05-21 Method of treating diabetes
IL165304A IL165304A (en) 2002-05-21 2004-11-18 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for preparation of pharmaceutical compositions for treatment of diabetes related conditions
IL213809A IL213809A0 (en) 2002-05-21 2011-06-28 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
IL213806A IL213806A0 (en) 2002-05-21 2011-06-28 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL165304A IL165304A (en) 2002-05-21 2004-11-18 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for preparation of pharmaceutical compositions for treatment of diabetes related conditions
IL213809A IL213809A0 (en) 2002-05-21 2011-06-28 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
IL213806A IL213806A0 (en) 2002-05-21 2011-06-28 Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions

Country Status (17)

Country Link
US (4) US20040063717A1 (xx)
EP (2) EP2332540A1 (xx)
JP (1) JP4546824B2 (xx)
KR (1) KR101030943B1 (xx)
CN (1) CN100551370C (xx)
AU (1) AU2003248558B8 (xx)
BR (1) BR0311161A (xx)
CA (1) CA2486712C (xx)
ES (1) ES2523873T3 (xx)
HK (1) HK1073441A1 (xx)
IL (4) IL165304A0 (xx)
MX (1) MXPA04011530A (xx)
NO (1) NO330336B1 (xx)
NZ (1) NZ536678A (xx)
RU (1) RU2320343C2 (xx)
WO (1) WO2003099281A2 (xx)
ZA (1) ZA200409331B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) * 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
KR20100015685A (ko) * 2007-04-12 2010-02-12 씨브이 쎄러퓨틱스, 인코포레이티드 인슐린 분비 강화를 위한 라놀라진
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
KR20100038322A (ko) * 2007-05-31 2010-04-14 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료 방법
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
KR20110013348A (ko) * 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 통증 치료를 위한 라놀라진의 용도
WO2010068913A2 (en) * 2008-12-11 2010-06-17 Mefford Scientific, Llc Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0283168A3 (en) * 1987-03-16 1989-06-14 American Home Products Corporation Fluorooxirane carboxylates
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ247044A (en) 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JP2002522082A (ja) * 1998-08-11 2002-07-23 ザ・ガバナーズ・オブ・ザ・ユニバーシティ・オブ・アルバータ 哺乳類マロニルＣｏＡデカルボキシラーゼの阻害剤、作用物質および拮抗物質を同定するための組成物および方法
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
KR20020075801A (ko) * 2000-02-18 2002-10-05 씨브이 쎄러퓨틱스, 인코포레이티드 울혈성 심부전 치료의 부분적 지방산 산화 방지제
FR2805463B1 (fr) * 2000-02-25 2003-01-24 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
US6706689B2 (en) 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
US20020052377A1 (en) 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
EP2039357A2 (en) 2001-01-26 2009-03-25 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
HUP0402088A3 (en) * 2001-07-19 2010-03-29 Cv Therapeutics Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
JP2005526024A (ja) 2002-02-08 2005-09-02 スミスクライン ビーチャム コーポレーション インスリン分泌を阻害するための化合物及びそれに関連する方法
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
CA2517981A1 (en) 2003-03-05 2004-09-16 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
CA2534816A1 (en) 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
EP1755579A4 (en) 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US20060111361A1 (en) 2004-11-09 2006-05-25 Brent Blackburn Method of reversing left ventricle remodeling
KR20070093988A (ko) 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
EP1865945A4 (en) 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
EP2101775A1 (en) 2006-12-21 2009-09-23 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
EP2117509A1 (en) 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008101012A1 (en) 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090312340A1 (en) 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
KR20100038322A (ko) 2007-05-31 2010-04-14 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료 방법
KR20110013348A (ko) 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 통증 치료를 위한 라놀라진의 용도
EP2337559A2 (en) 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation
US20100130436A1 (en) 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
WO2010132696A1 (en) 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension

Also Published As

Publication number Publication date
AU2003248558B2 (en) 2009-03-12
WO2003099281A3 (en) 2004-04-01
EP2332540A1 (en) 2011-06-15
KR20040111677A (ko) 2004-12-31
RU2004133670A (ru) 2005-06-10
NO330336B1 (no) 2011-03-28
US20130102555A1 (en) 2013-04-25
HK1073441A1 (en) 2005-10-07
US8314104B2 (en) 2012-11-20
ZA200409331B (en) 2005-06-29
IL213809A0 (en) 2011-07-31
US20140378465A1 (en) 2014-12-25
CN100551370C (zh) 2009-10-21
NO20045554L (no) 2004-12-20
MXPA04011530A (es) 2005-08-15
US20100197701A1 (en) 2010-08-05
CA2486712C (en) 2012-01-03
JP2005532331A (ja) 2005-10-27
RU2320343C2 (ru) 2008-03-27
IL165304A (en) 2011-08-31
WO2003099281A2 (en) 2003-12-04
US20040063717A1 (en) 2004-04-01
BR0311161A (pt) 2005-03-29
CN1652788A (zh) 2005-08-10
IL213806A0 (en) 2011-07-31
ES2523873T3 (es) 2014-12-02
AU2003248558B8 (en) 2009-07-09
JP4546824B2 (ja) 2010-09-22
US8883750B2 (en) 2014-11-11
NZ536678A (en) 2007-01-26
AU2003248558A1 (en) 2003-12-12
KR101030943B1 (ko) 2011-04-28
EP1505977A2 (en) 2005-02-16
EP1505977B1 (en) 2014-09-10
CA2486712A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
IL218909A0 (en) Treatment of diabetes
AU2003226301A8 (en) Method of treating cancer
ZA200409331B (en) Method of treating diabetes
AU2003283958A8 (en) Method of treating tremors
AU2003256847A8 (en) Method of treating cancer
EP1577280A4 (en) DEUTERATION PROCESS
IL166600A0 (en) Method of treating osteoarthritis
IL165242A0 (en) Treatment for diabetes
IL163737A0 (en) Method of treating mucus hypersecretion
GB0306309D0 (en) Method of treatment
GB0302572D0 (en) Method of treatment
ZA200303274B (en) Method of treating shellfish.
EP1493716A4 (en) METHOD OF WASTE WATER TREATMENT
IL154293A0 (en) Process of treating dates
EP1553965A4 (en) TUMOR TREATMENT METHOD
GB0208897D0 (en) New method of treatment
AU2003299652A8 (en) Methods for treating diabetes
PL376350A1 (en) Sludge treatment method
GB0217493D0 (en) Novel methods of treatment
AU2003252188A8 (en) Method of ore treatment
AU2002951913A0 (en) Method of treatment
GB0221712D0 (en) Methods of treatment
AU2003236232A1 (en) Method for treatment of textile
GB0400094D0 (en) The method of treating tuberculosis
GB0213198D0 (en) Method of treatment